Sarah Flossdorf
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sarah Flossdorf has a total of 193 co-authors. Here are the top co-authors by number of shared publications:
- Matthias Stelljes
University of Muenster, Muenster, Germany
6 shared publications - Katharina Fleischhauer
Institute for Experimental Cellular Therapy, University Hospital Essen, Essen, Germany
4 shared publications - Nicolaus Kröger
University Hospital Eppendorf, Hamburg, Germany
4 shared publications - Bastian von Tresckow
Department of Hematology and Stem Cell Transplantation, West German Cancer Center and German Cancer Consortium (DKTK partner site Essen), University Hospital Essen, University of Duisburg-Essen, Essen, Germany
3 shared publications - Johannes Schetelig
Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus, TU Dresden, Dresden, Germany
3 shared publications Nicolaus Kröger
German Registry for Hematopoietic Stem Cell Transplantation and Cell Therapy (DRST), Frankfurt, Germany
3 shared publications
Latest Publications
- 24 November 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (22) , 7797-7808
Novel KIR2DS4:HLA-B∗35 interaction predicts HLA-B∗35+ patient survival after hematopoietic stem cell transplant
Haploidentical hematopoietic cell transplant (haploHCT) is an integral treatment paradigm for patients with leukemia. Although overall survival (OS) after haploHCT has steadily improved, relapse-free survival (RFS) remains relatively stagnant. Upon the discovery of killer immunoglobulin-like receptors (KIRs) on natural killer (NK) cells and their cognate HLA ligands, algorithms have been developed to enhance graft-versus-leukemia effects. However, these algorithms fail to yield consistent predictions in patient outcomes. We used a combination of in silico protein folding and interactions to determine KIR:HLA reactivity in conjunction with in vitro acoustic force microscopy to measure cell avidity (CA) as a readout for KIR signal strength. CA was determined using monoallelic HLA expressing K562 cell lines, monoallelic KIR Jurkat cells, and peripheral blood NK cells. We discovered that HLA-B∗35 interacts with KIR2DS4. We applied the newly discovered interaction to predict outcomes for patients who underwent HCT. Stratifying patients based on their HLA-B∗35 positivity and donor KIR2DS4 status, we delineated a correlation to survival (P = .061) when donors only had full-length KIR2DS4. Patients who received a haploHCT and NK cell addback from donors with only full-length KIR2DS4 had a significantly improved RFS (P = .001) and OS (P = .016) compared with truncated (KIR1D) and full-length KIR2DS4 donors. This was independently validated in a diverse 10/10 HLA-matched European cohort with RFS (P = .0255) and OS (P = .0388). Thus, the identified novel KIR2DS4:HLA-B∗35 interaction axis predicts patient survival, in both haploHCT and fully matched HCT, and highlights that our current understanding of the KIR:HLA interactome is incomplete and requires remapping for enhanced therapeutic applications.
- 24 November 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (22) , 7797-7808
Novel KIR2DS4:HLA-B∗35 interaction predicts HLA-B∗35+ patient survival after hematopoietic stem cell transplant
Haploidentical hematopoietic cell transplant (haploHCT) is an integral treatment paradigm for patients with leukemia. Although overall survival (OS) after haploHCT has steadily improved, relapse-free survival (RFS) remains relatively stagnant. Upon the discovery of killer immunoglobulin-like receptors (KIRs) on natural killer (NK) cells and their cognate HLA ligands, algorithms have been developed to enhance graft-versus-leukemia effects. However, these algorithms fail to yield consistent predictions in patient outcomes. We used a combination of in silico protein folding and interactions to determine KIR:HLA reactivity in conjunction with in vitro acoustic force microscopy to measure cell avidity (CA) as a readout for KIR signal strength. CA was determined using monoallelic HLA expressing K562 cell lines, monoallelic KIR Jurkat cells, and peripheral blood NK cells. We discovered that HLA-B∗35 interacts with KIR2DS4. We applied the newly discovered interaction to predict outcomes for patients who underwent HCT. Stratifying patients based on their HLA-B∗35 positivity and donor KIR2DS4 status, we delineated a correlation to survival (P = .061) when donors only had full-length KIR2DS4. Patients who received a haploHCT and NK cell addback from donors with only full-length KIR2DS4 had a significantly improved RFS (P = .001) and OS (P = .016) compared with truncated (KIR1D) and full-length KIR2DS4 donors. This was independently validated in a diverse 10/10 HLA-matched European cohort with RFS (P = .0255) and OS (P = .0388). Thus, the identified novel KIR2DS4:HLA-B∗35 interaction axis predicts patient survival, in both haploHCT and fully matched HCT, and highlights that our current understanding of the KIR:HLA interactome is incomplete and requires remapping for enhanced therapeutic applications.
- Open Access
- 11 September 2026
- Published by Wiley in European Journal of Haematology
Transplantation Strategies in Treatment of Primary Plasma Cell Leukemia in Germany—A Multi‐Center Analysis
Objectives: Primary plasma cell leukemia (pPCL) is a rare disease with poor outcomes. As data on randomized phase‐III trials are lacking, treatment recommendations are predominately based on retrospective analyses incorporating time periods with outdated therapies. Thus, the optimal consolidation strategy remains to be defined. Methods: We conducted a retrospective, multi‐center analysis with 49 transplant‐eligible patients diagnosed with pPCL between 2011 and 2025 focusing on different stem cell transplantation (SCT) strategies as consolidation treatment in first remission: single autologous (auto) or single allogeneic (allo) SCT versus patients with tandem cell therapy strategies (auto‐auto, allo‐auto, auto‐chimeric antigen receptor therapy). Results: The median follow‐up after first SCT was 31 months. The cumulative incidence of initiating next treatment was lower after tandem cell therapy compared to single SCT (at 12 months: 42% vs. 57%, p = 0.006). Moreover, in a multivariable analysis incorporating cytogenetic risk and response to induction therapy, tandem transplantation strategies tended to be the only independent predictor for prolonged time to next treatment (TTNT, p = 0.077). Noteworthy, differences in TTNT between patients with a single SCT and patients with tandem cell therapy did not translate into an improved overall survival, possibly due to potent salvage therapies. Conclusions: Our data support recent recommendations advising treating patients with tandem transplantation regimes.
- 11 September 2026
- Published by Wiley in European Journal of Haematology
Open AccessTransplantation Strategies in Treatment of Primary Plasma Cell Leukemia in Germany—A Multi‐Center Analysis
Objectives: Primary plasma cell leukemia (pPCL) is a rare disease with poor outcomes. As data on randomized phase‐III trials are lacking, treatment recommendations are predominately based on retrospective analyses incorporating time periods with outdated therapies. Thus, the optimal consolidation strategy remains to be defined. Methods: We conducted a retrospective, multi‐center analysis with 49 transplant‐eligible patients diagnosed with pPCL between 2011 and 2025 focusing on different stem cell transplantation (SCT) strategies as consolidation treatment in first remission: single autologous (auto) or single allogeneic (allo) SCT versus patients with tandem cell therapy strategies (auto‐auto, allo‐auto, auto‐chimeric antigen receptor therapy). Results: The median follow‐up after first SCT was 31 months. The cumulative incidence of initiating next treatment was lower after tandem cell therapy compared to single SCT (at 12 months: 42% vs. 57%, p = 0.006). Moreover, in a multivariable analysis incorporating cytogenetic risk and response to induction therapy, tandem transplantation strategies tended to be the only independent predictor for prolonged time to next treatment (TTNT, p = 0.077). Noteworthy, differences in TTNT between patients with a single SCT and patients with tandem cell therapy did not translate into an improved overall survival, possibly due to potent salvage therapies. Conclusions: Our data support recent recommendations advising treating patients with tandem transplantation regimes.
- Open Access
- 23 June 2026
- Published by SAGE Publications in Cephalalgia Reports
- Vol. 9
Response to “Beyond headache days: Refining the framework for understanding CGRP monoclonal antibody discontinuation”
- 23 June 2026
- Published by SAGE Publications in Cephalalgia Reports
- Vol. 9
Open AccessResponse to “Beyond headache days: Refining the framework for understanding CGRP monoclonal antibody discontinuation”
- Open Access
- 16 June 2026
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (10) , 1301.e1-1301.e10
Allogeneic Transplantation in the rare disease MDS/MPN with Neutrophilia: Age and Disease Burden Determine Outcome
- 16 June 2026
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (10) , 1301.e1-1301.e10
Open AccessAllogeneic Transplantation in the rare disease MDS/MPN with Neutrophilia: Age and Disease Burden Determine Outcome
- Open Access
- 12 April 2026
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (8) , 962.e1-962.e15
Survival Trends in Young Adults With Acute Leukaemia After AHSCT in Germany: Comparisons With Younger and Older Patients
- 12 April 2026
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (8) , 962.e1-962.e15
Open AccessSurvival Trends in Young Adults With Acute Leukaemia After AHSCT in Germany: Comparisons With Younger and Older Patients
- Open Access
- 8 April 2026
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 61 (6) , 694-701
Haploidentical transplantation with post-transplant cyclophosphamide is not inferior to 9/10-MUD transplantation with ATG in patients with myeloid malignancies
The selection of the best available donor is crucial for patients’ outcome after allogeneic stem cell transplantation (allo-SCT). In the absence of fully Human leucocyte antigen (HLA) -matched donors, mismatched unrelated donor (9/10-MUD) or haploidentical donor (haplo) can be considered. No consensus has been reached on the best alternative and large real-world data are warranted to support decisional processes. We compared the outcome of 1413 patients with myeloid malignancies undergoing allo-SCT from 9/10-MUD with anti-thymocyte-globulin (ATG) ( n = 1134) or haplo with post-transplant cyclophosphamide (PT-Cy, n = 279) between 2009 and 2020 in 48 German centres. Donor type with related graft versus host disease (GvHD) prophylaxis showed in multivariable analysis no significant impact on acute GvHD development, both grade II-IV (HR 0.90, 95% CI 0.69–1.19, p = 0.469) and severe (HR 1.22, 95% CI 0.82-1.81, p = 0.319), nor on moderate to severe chronic GvHD (HR 0.78, 95% CI 0.59–1.03, p = 0.077). Moreover, no influence from donor type was observed on GVHD-relapse-free survival (HR 1.12, 95% CI 0.92–1.36, p = 0.227), progression-free survival (HR 1.2, 95% CI 0.95–1.51, p = 0.121), non-relapse mortality (HR 1.1, 95% CI 0.81–1.51, p = 0.542) and overall survival (HR 1.16, 95% CI 0.91–1.48, p = 0.235). Our real-world data demonstrate that haplo allo-SCT with PT-Cy is not inferior to 9/10-MUD allo-SCT with ATG.
- 8 April 2026
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 61 (6) , 694-701
Open AccessHaploidentical transplantation with post-transplant cyclophosphamide is not inferior to 9/10-MUD transplantation with ATG in patients with myeloid malignancies
The selection of the best available donor is crucial for patients’ outcome after allogeneic stem cell transplantation (allo-SCT). In the absence of fully Human leucocyte antigen (HLA) -matched donors, mismatched unrelated donor (9/10-MUD) or haploidentical donor (haplo) can be considered. No consensus has been reached on the best alternative and large real-world data are warranted to support decisional processes. We compared the outcome of 1413 patients with myeloid malignancies undergoing allo-SCT from 9/10-MUD with anti-thymocyte-globulin (ATG) ( n = 1134) or haplo with post-transplant cyclophosphamide (PT-Cy, n = 279) between 2009 and 2020 in 48 German centres. Donor type with related graft versus host disease (GvHD) prophylaxis showed in multivariable analysis no significant impact on acute GvHD development, both grade II-IV (HR 0.90, 95% CI 0.69–1.19, p = 0.469) and severe (HR 1.22, 95% CI 0.82-1.81, p = 0.319), nor on moderate to severe chronic GvHD (HR 0.78, 95% CI 0.59–1.03, p = 0.077). Moreover, no influence from donor type was observed on GVHD-relapse-free survival (HR 1.12, 95% CI 0.92–1.36, p = 0.227), progression-free survival (HR 1.2, 95% CI 0.95–1.51, p = 0.121), non-relapse mortality (HR 1.1, 95% CI 0.81–1.51, p = 0.542) and overall survival (HR 1.16, 95% CI 0.91–1.48, p = 0.235). Our real-world data demonstrate that haplo allo-SCT with PT-Cy is not inferior to 9/10-MUD allo-SCT with ATG.
- Open Access
- 13 March 2026
- Published by SAGE Publications in Cephalalgia Reports
- Vol. 9
Reasons for discontinuation of CGRP antibody therapy: Insights from a retrospective real-world cohort study
Aim: Calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) have expanded preventive treatment options for migraine, especially in patients with previous prophylactic failures. While their efficacy and tolerability are well established, reasons for treatment discontinuation remain insufficiently characterized. This study aimed to systematically evaluate discontinuation rates and underlying reasons for stopping CGRP mAb therapy in a real-world cohort of drug-resistant migraine patients. Methods: This retrospective, single-center cohort study included adults with episodic or chronic migraine treated with erenumab, galcanezumab, or fremanezumab at the West German Headache Center. Baseline clinical characteristics, monthly headache and migraine days, and acute medication intake were extracted from routine clinical documentation. Treatment status was assessed via medical records and telephone verification. Reasons for discontinuation were self-reported and categorized as perceived lack of effectiveness, adverse events, or subjective remission. Results: Of 252 included patients, 74.6% ( n = 188) continued therapy, while 25.4% ( n = 64) discontinued. Perceived ineffectiveness was the most common reason for discontinuation (67.2%, n = 43), and 76.7% ( n = 33) of these patients stopped within six months. Only 9.3% ( n = 4) reported secondary loss of effectiveness after an initial response. Patient-reported qualitative improvements—such as reduced attack intensity or duration—were frequent among patients who continued treatment, even when formal response criteria based on monthly headache days (MHDs) were not met. Prior responsiveness to triptans was associated with continuation of therapy. Conclusion: In this real-world cohort of drug-resistant migraine, treatment persistence with CGRP mAbs was high. Most discontinuations occurred within six months and were driven by perceived lack of effectiveness. Qualitative improvements beyond reductions in MHDs were important factors contributing to continued therapy. These findings highlight the relevance of patient-reported improvements in clinical decision-making.
- 13 March 2026
- Published by SAGE Publications in Cephalalgia Reports
- Vol. 9
Open AccessReasons for discontinuation of CGRP antibody therapy: Insights from a retrospective real-world cohort study
Aim: Calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) have expanded preventive treatment options for migraine, especially in patients with previous prophylactic failures. While their efficacy and tolerability are well established, reasons for treatment discontinuation remain insufficiently characterized. This study aimed to systematically evaluate discontinuation rates and underlying reasons for stopping CGRP mAb therapy in a real-world cohort of drug-resistant migraine patients. Methods: This retrospective, single-center cohort study included adults with episodic or chronic migraine treated with erenumab, galcanezumab, or fremanezumab at the West German Headache Center. Baseline clinical characteristics, monthly headache and migraine days, and acute medication intake were extracted from routine clinical documentation. Treatment status was assessed via medical records and telephone verification. Reasons for discontinuation were self-reported and categorized as perceived lack of effectiveness, adverse events, or subjective remission. Results: Of 252 included patients, 74.6% ( n = 188) continued therapy, while 25.4% ( n = 64) discontinued. Perceived ineffectiveness was the most common reason for discontinuation (67.2%, n = 43), and 76.7% ( n = 33) of these patients stopped within six months. Only 9.3% ( n = 4) reported secondary loss of effectiveness after an initial response. Patient-reported qualitative improvements—such as reduced attack intensity or duration—were frequent among patients who continued treatment, even when formal response criteria based on monthly headache days (MHDs) were not met. Prior responsiveness to triptans was associated with continuation of therapy. Conclusion: In this real-world cohort of drug-resistant migraine, treatment persistence with CGRP mAbs was high. Most discontinuations occurred within six months and were driven by perceived lack of effectiveness. Qualitative improvements beyond reductions in MHDs were important factors contributing to continued therapy. These findings highlight the relevance of patient-reported improvements in clinical decision-making.
- Open Access
- 2 October 2025
- Published by American Society of Hematology in Blood
- Vol. 146 (14) , 1677-1686
Remission conversion drives outcomes after CAR T-cell therapy for multiple myeloma: a registry analysis from the DRST
Cellular therapies targeting B-cell maturation antigen have shown promise in controlled clinical trials, but their impact in broader, diverse patient populations remains underexplored. This study examines the real-world efficacy and safety in 343 triple-class–exposed patients with relapsed and refractory multiple myeloma who received idecabtagene vicleucel (ide-cel; n = 266) or ciltacabtagene autoleucel (cilta-cel; n = 77) after >3 previous lines of therapy in Germany. Cilta-cel, compared with ide-cel, demonstrated superior outcomes, achieving a higher overall response rate (94% vs 82%) and 10-month progression-free survival (PFS; 76% vs 47%). Cilta-cel also led to higher complete response (CR; 61% vs 39%) and improved response conversion, with more patients achieving CR after starting from less than CR before chimeric antigen receptor T-cell (CAR T) therapy. For those attaining CR after therapy, cilta-cel showed longer PFS, especially in patients who entered treatment with a partial response or worse. Cytokine release syndrome was observed in 85% of cilta-cel and 81% of ide-cel cases, predominantly low grade. Immune effector cell–associated neurotoxicity syndrome was more common with cilta-cel (25% vs 15%), although nonrelapse mortality at 10 months was comparable between therapies (7% vs 5%). Weighted multivariable analysis after propensity score matching confirmed a significant advantage in terms of PFS for cilta-cel, with a hazard ratio of 0.48. Overall, outcomes in our registry analysis were comparable with the pivotal trials that led to approval of the respective agents. Cilta-cel demonstrated a greater capacity for response conversion and durable remission. These findings underscore the need for individualized CAR T therapy selection to optimize patient outcomes.
- 2 October 2025
- Published by American Society of Hematology in Blood
- Vol. 146 (14) , 1677-1686
Open AccessRemission conversion drives outcomes after CAR T-cell therapy for multiple myeloma: a registry analysis from the DRST
Cellular therapies targeting B-cell maturation antigen have shown promise in controlled clinical trials, but their impact in broader, diverse patient populations remains underexplored. This study examines the real-world efficacy and safety in 343 triple-class–exposed patients with relapsed and refractory multiple myeloma who received idecabtagene vicleucel (ide-cel; n = 266) or ciltacabtagene autoleucel (cilta-cel; n = 77) after >3 previous lines of therapy in Germany. Cilta-cel, compared with ide-cel, demonstrated superior outcomes, achieving a higher overall response rate (94% vs 82%) and 10-month progression-free survival (PFS; 76% vs 47%). Cilta-cel also led to higher complete response (CR; 61% vs 39%) and improved response conversion, with more patients achieving CR after starting from less than CR before chimeric antigen receptor T-cell (CAR T) therapy. For those attaining CR after therapy, cilta-cel showed longer PFS, especially in patients who entered treatment with a partial response or worse. Cytokine release syndrome was observed in 85% of cilta-cel and 81% of ide-cel cases, predominantly low grade. Immune effector cell–associated neurotoxicity syndrome was more common with cilta-cel (25% vs 15%), although nonrelapse mortality at 10 months was comparable between therapies (7% vs 5%). Weighted multivariable analysis after propensity score matching confirmed a significant advantage in terms of PFS for cilta-cel, with a hazard ratio of 0.48. Overall, outcomes in our registry analysis were comparable with the pivotal trials that led to approval of the respective agents. Cilta-cel demonstrated a greater capacity for response conversion and durable remission. These findings underscore the need for individualized CAR T therapy selection to optimize patient outcomes.
- 12 August 2025
- Published by Georg Thieme Verlag KG in Transfusionsmedizin
- Vol. 15 (03) , 130-140
Entwicklung der Stammzelltransplantation und Zelltherapie in Deutschland: Bericht aus dem Deutschen Register für hämatopoetische Stammzelltransplantation und Zelltherapie (DRST)
Zusammenfassung: Das Deutsche Register für hämatopoetische Stammzelltransplantation und Zelltherapie (DRST) führt die Registrierung der klinischen Aktivität der autologen und allogenen Blutstammzelltransplantation sowie der zellulären Therapien in Deutschland datenschutzrechtlich konform und in dokumentierter trilateraler Übereinkunft mit den klinischen Zentren und der European Society for Blood and Marrow Transplantation (EBMT) durch. Aktuell sind über 88 000 autologe und fast 70 000 allogene Stammzelltransplantationen sowie mehr als 3600 chimeric antigen receptor T-Zell-Therapien (CAR-T) im DRST verzeichnet. Aus den über 25 Jahren dieser Aufzeichnungen ergibt sich in den letzten Jahren ein leichter Rückgang der autologen Stammzelltransplantationen, vermutlich aufgrund alternativer Therapieformen. Hingegen lässt sich bei den allogenen Stammzelltransplantationen weiterhin ein Anstieg verzeichnen, was auf einen starken Anstieg des Alters der Patienten, denen diese Therapiemöglichkeit angeboten werden kann, sowie auf eine Anpassung der Indikationsstellung hin zu akuten Leukämien und myeloischen Neoplasien zurückzuführen ist. Die CAR-T-Aktivität ist vor allem für das multiple Myelom angestiegen, und es ist zu erwarten, dass dieser Trend sich mit Einschluss weiterer Entitäten wie den Autoimmunerkrankungen weiter fortsetzt. Durch das DRST werden zudem retrospektive Studien zu spezifischen Fragestellungen ermöglicht, was seine wichtige Rolle für medizinische, wissenschaftliche und gesundheitspolitische Fragen unterstreicht.
- 12 August 2025
- Published by Georg Thieme Verlag KG in Transfusionsmedizin
- Vol. 15 (03) , 130-140
Entwicklung der Stammzelltransplantation und Zelltherapie in Deutschland: Bericht aus dem Deutschen Register für hämatopoetische Stammzelltransplantation und Zelltherapie (DRST)
Zusammenfassung: Das Deutsche Register für hämatopoetische Stammzelltransplantation und Zelltherapie (DRST) führt die Registrierung der klinischen Aktivität der autologen und allogenen Blutstammzelltransplantation sowie der zellulären Therapien in Deutschland datenschutzrechtlich konform und in dokumentierter trilateraler Übereinkunft mit den klinischen Zentren und der European Society for Blood and Marrow Transplantation (EBMT) durch. Aktuell sind über 88 000 autologe und fast 70 000 allogene Stammzelltransplantationen sowie mehr als 3600 chimeric antigen receptor T-Zell-Therapien (CAR-T) im DRST verzeichnet. Aus den über 25 Jahren dieser Aufzeichnungen ergibt sich in den letzten Jahren ein leichter Rückgang der autologen Stammzelltransplantationen, vermutlich aufgrund alternativer Therapieformen. Hingegen lässt sich bei den allogenen Stammzelltransplantationen weiterhin ein Anstieg verzeichnen, was auf einen starken Anstieg des Alters der Patienten, denen diese Therapiemöglichkeit angeboten werden kann, sowie auf eine Anpassung der Indikationsstellung hin zu akuten Leukämien und myeloischen Neoplasien zurückzuführen ist. Die CAR-T-Aktivität ist vor allem für das multiple Myelom angestiegen, und es ist zu erwarten, dass dieser Trend sich mit Einschluss weiterer Entitäten wie den Autoimmunerkrankungen weiter fortsetzt. Durch das DRST werden zudem retrospektive Studien zu spezifischen Fragestellungen ermöglicht, was seine wichtige Rolle für medizinische, wissenschaftliche und gesundheitspolitische Fragen unterstreicht.
- Open Access
- 8 April 2025
- Published by Springer Nature in Blood Cancer Journal
- Vol. 15 (1) , 1-4
Real-world experience with first-line CPX-351 treatment in patients with acute myeloid leukemia – long-term follow-up with focus on younger patients
- 8 April 2025
- Published by Springer Nature in Blood Cancer Journal
- Vol. 15 (1) , 1-4
Open AccessReal-world experience with first-line CPX-351 treatment in patients with acute myeloid leukemia – long-term follow-up with focus on younger patients